Heron Therapeutics Inc’s recent filing unveils that its 10% Owner Rubric Capital Management LP acquired Company’s shares for reported $3.58 million on Aug 08 ’25. In the deal valued at $1.50 per share,2,387,225 shares were bought. As a result of this transaction, Rubric Capital Management LP now holds 29,100,728 shares worth roughly $38.12 million.
Then, Morgan Adam bought 1,766,546 shares, generating $2,649,819 in total proceeds. Upon buying the shares at $1.50, the Director now owns 8,753,290 shares.
H.C. Wainwright initiated its Heron Therapeutics Inc [HRTX] rating to a Buy in a research note published on June 09, 2025; the price target was $6. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who began to cover the stock in mid June with a ‘”a Buy”‘ rating. CapitalOne began covering HRTX with “an Overweight” recommendation on April 23, 2024. Needham maintained its rating on March 13, 2024. It rated HRTX as “a Buy”.
Price Performance Review of HRTX
On Tuesday, Heron Therapeutics Inc [NASDAQ:HRTX] saw its stock jump 2.34% to $1.31. Over the last five days, the stock has lost -27.62%. Heron Therapeutics Inc shares have fallen nearly -38.64% since the year began. Nevertheless, the stocks have fallen -14.38% over the past one year. While a 52-week high of $2.68 was reached on 03/05/25, a 52-week low of $1.04 was recorded on 08/11/25.
Levels Of Support And Resistance For HRTX Stock
The 24-hour chart illustrates a support level at 1.2637, which if violated will result in even more drops to 1.2174. On the upside, there is a resistance level at 1.3426. A further resistance level may holdings at 1.3752.
How much short interest is there in Heron Therapeutics Inc?
A steep rise in short interest was recorded in Heron Therapeutics Inc stocks on 2025-07-31, dropping by -1.67 million shares to a total of 35.26 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 36.92 million shares. There was a decline of -4.73%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 27, 2020 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $24 price target.
